Skip to Content
E. Jason Abel, MD, FACS

Contact Dr. Abel


(608) 262-2691

UW Medical Foundation Centennial Building
1685 Highland Ave
Madison, WI 53705-2281

E. Jason Abel, MD, FACS

Assistant Professor
Department of Urology


  • BS, Zoology; BA, Molecular Biology, University of Texas at Austin, 1998
  • MD, The University of Texas at Houston Medical School, 2003
  • Residency, University of Utah Division of Urology, Salt Lake City, UT, 2008
  • Fellowship, Urologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2010

Dr. Abel specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

Clinical Specialties

Dr. Abel is certified by the American Board of Urology. He performs open and laparoscopic surgery including surgery using the daVinci robot. Dr Abel’s philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Research Interests

Dr. Abel conducts clinical, translational, and basic research in urologic oncology. Clinical and translational interests include improving patient outcomes after complex urologic surgery, improving prognostic ability for patient decision making, and multidisciplinary care of kidney cancer.

Dr. Abel serves on the board of directors for the Society of Urologic Oncology (SUO) Clinical Trials Consortium.

  • Role of NFXB/HIF2A Axis in Renal Cell Carcinoma Progression
    Funding Agency: National Institutes of Health (NIH); National Cancer Institute (NCI) Career Development Award 1K08CA178168-01
    Principal Investigator(s): E. Jason Abel, MD, FACS
    More Information

Recent Publications
  • Abel EJ, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT, Huang W, Ziemlewicz T. Multi-quadrant biopsy technique improves diagnostic ability in large heterogeneous renal masses. J. Urol. 2015 Mar 30.
    [PubMed ID: 25837535]
    More Information
  • Prince J, Bultman E, Hinshaw L, Drewry A, Blute M, Best S, Lee FT, Ziemlewicz T, Lubner M, Shi F, Nakada SY, Abel EJ. Patient and Tumor Characteristics can Predict Nondiagnostic Renal Mass Biopsy Findings. J. Urol. 2015 Jun; 193(6):1899-904.
    [PubMed ID: 25498574]
    More Information
  • Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P, Devon ON, Tarrell RF, Frank I, Jarrard DF, Downs TM, Boorjian SA. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur. Urol. 2014 Dec; 66(6):1139-47.
    [PubMed ID: 25194909]
    More Information
  • Moreland AJ, Ziemlewicz TJ, Best SL, Hinshaw JL, Lubner MG, Alexander ML, Brace CL, Kitchin DR, Hedican SP, Nakada SY, Lee FT, Abel EJ. High-powered microwave ablation of t1a renal cell carcinoma: safety and initial clinical evaluation. J. Endourol. 2014 Sep; 28(9):1046-52.
    [PubMed ID: 24846329]
    More Information
  • Haddad AQ, Wood CG, Abel EJ, Krabbe LM, Darwish OM, Thompson RH, Heckman JE, Merril MM, Gayed BA, Sagalowsky AI, Boorjian SA, Margulis V, Leibovich BC. Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. J. Urol. 2014 Oct; 192(4):1050-6.
    [PubMed ID: 24704115]
    More Information
  • Abel EJ, Wong K, Sado M, Leverson GE, Patel SR, Downs TM, Jarrard DF. Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS 2014 Apr-Jun; 18(2):282-7.
    [PubMed ID: 24960494, PMCID: 4035641]
    More Information
  • Potretzke A, Hillman L, Wong K, Shi F, Brower R, Mai S, Cetnar JP, Abel EJ, Downs TM. NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder. Urol. Oncol. 2014 Jul; 32(5):631-6.
    [PubMed ID: 24629498]
    More Information
  • Abel EJ, Carrasco A, Karam J, Tamboli P, Delacroix S, Vaporciyan AA, Wood CG. Positive vascular wall margins have minimal impact on cancer outcomes in patients with non-metastatic renal cell carcinoma (RCC) with tumour thrombus. BJU Int. 2014 Nov; 114(5):667-73.
    [PubMed ID: 24128265]
    More Information
  • Abel EJ, Bauman TM, Weiker M, Shi F, Downs TM, Jarrard DF, Huang W. Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. Hum. Pathol. 2014 May; 45(5):1092-9.
    [PubMed ID: 24746216, PMCID: 4134351]
    More Information
  • Abel EJ, Thompson RH, Margulis V, Heckman JE, Merril MM, Darwish OM, Krabbe LM, Boorjian SA, Leibovich BC, Wood CG. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur. Urol. 2014 Sep; 66(3):584-92.
    [PubMed ID: 24262104]
    More Information Copyright © 2015 The Board of Regents of the University of Wisconsin System